Loading clinical trials...
Loading clinical trials...
A Phase 2A Safety and Biomarker Study of EPI-589 in Subjects With Amyotrophic Lateral Sclerosis
Conditions
Interventions
EPI-589
Locations
3
United States
Cedar's Sinai
Los Angeles, California, United States
California Pacific Medical Center
San Francisco, California, United States
Providence Brain and Spine Institute ALS Center
Portland, Oregon, United States
Start Date
January 14, 2016
Primary Completion Date
February 23, 2018
Completion Date
February 23, 2018
Last Updated
October 14, 2020
NCT05204017
NCT07322003
NCT07414212
NCT07401121
NCT05104710
NCT03233646
Lead Sponsor
PTC Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions